Y/E FinancialsJust as predicted. The Y/E financials showed a modest year-over-year gain, which continues to show positive steps in the right direction and the EPS remained at (0.01) which is far, far better than other companies in this sector in regards to MDMA-assisted therapy. Hopefully the recently signed contracts and future contracts will move the company to profitability in the coming year. The major key to this company's long-term success is the intellectual property. Well done to Nick and the team at PharmAla!